Table 2.

Consensus statements for AL diagnostic tests in clinical practice.

Barriers to exclude AL amyloidosis	Cardiology consensus rate %a
Periodic or permanent access difficulties to sFLC, SPIE, and UPIE, periodic test kit supply problems, and lack of specialists in clinics to interpret test results form a barrier to exclude AL amyloidosis.	60
Recommendations to obtain a timely and accurate AL amyloidosis assessment	Cardiology Consensus rate %a
Clinical, ECG, and echocardiography findings of the patients are often satisfactory to suspect CA; therefore, patients with suspected CA can directly be referred to sFLC, SPIE, and UPIE without resorting to CMR.	100
In a patient with suspected CA (based on clinical, ECG, and echocardiography findings), sFLC, SPIE, and UPIE tests should be concluded before or concurrently with bone scintigraphy if it is possible to access these tests and their interpreter specialists within a reasonable time.	90
Bone scintigraphy should be performed without a delay in patients with suspected CA (based on clinical, ECG, and echocardiography findings) if sFLC, SPIE, and UPIE results excluded AL, or when delayed access/results are likely for sFLC, SPIE, and UPIE.	90
The absence of a monoclonal gammopathy by sFLC, SPIE, and UPIE mostly exclude AL amyloidosis.	100
A definitive diagnosis should not be established in patients with suspected CA until sFLC, SPIE, and UPIE are concluded, regardless of bone scintigraphy result.	90
Difficulties to access AL tests or interpret test results could be overcome by collaborating with external clinics or private laboratories.	100

^a Consensus was defined as when 80%–100% of the panel members marked the “agree/strongly agree” or “disagree/strongly disagree” option.